Singapore-based firm on track to commercialise cancer drug

Singapore

SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.

A Singapore-based biotechnology firm has emerged ahead of the very crowded research field of T-cell immunotherapy, by conducting the world's first US Food and Drug Administration (FDA) Phase Three cancer T-cell therapy trial involving a number of hospitals and treatment centres across the world.

This means Tessa Therapeutics will produce the world's first commercial T-cell therapy treatment for solid tumours.

Tessa announced last week that it has set up a multi-year strategic alliance with …